Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine as adjunct to multimodal analgesia in open gynecologic oncology surgery
ChiCTR2200062726Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postoperative pain and Delayed postoperative recovery (DPR) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Quality of recovery at postoperative day 2. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative painDelayed postoperative recovery (DPR)
Beyond the preview
Go deeper on ChiCTR2200062726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062726.